BioNTech SE (NASDAQ:BNTX) Shares Bought by Gallacher Capital Management LLC

Gallacher Capital Management LLC boosted its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 24.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,262 shares of the company’s stock after acquiring an additional 642 shares during the period. Gallacher Capital Management LLC’s holdings in BioNTech were worth $301,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Neuberger Berman Group LLC acquired a new position in shares of BioNTech in the fourth quarter valued at approximately $1,562,000. Truist Financial Corp acquired a new position in shares of BioNTech in the fourth quarter valued at approximately $1,445,000. Fifth Third Bancorp grew its holdings in BioNTech by 3,881.3% in the fourth quarter. Fifth Third Bancorp now owns 16,642 shares of the company’s stock valued at $1,756,000 after purchasing an additional 16,224 shares during the period. US Bancorp DE grew its holdings in BioNTech by 420.7% in the fourth quarter. US Bancorp DE now owns 28,614 shares of the company’s stock valued at $3,020,000 after purchasing an additional 23,119 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in BioNTech by 17.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock valued at $19,301,000 after purchasing an additional 26,777 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. UBS Group lowered their target price on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a report on Wednesday, March 27th. Canaccord Genuity Group reiterated a “buy” rating and set a $171.00 price objective on shares of BioNTech in a research note on Thursday, March 21st. HC Wainwright reiterated a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research note on Wednesday, June 26th. Evercore ISI initiated coverage on shares of BioNTech in a research note on Tuesday, May 14th. They set an “inline” rating and a $100.00 price objective for the company. Finally, BMO Capital Markets decreased their price objective on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, May 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $111.70.

BioNTech Stock Down 0.7 %

BNTX traded down $0.62 during trading on Friday, hitting $84.08. The company had a trading volume of 497,084 shares, compared to its average volume of 708,553. The company has a market cap of $19.99 billion, a PE ratio of 169.40 and a beta of 0.23. The business has a 50-day moving average of $90.76 and a 200-day moving average of $93.32. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. BioNTech SE has a 1-year low of $78.02 and a 1-year high of $125.83.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The company had revenue of $203.69 million during the quarter, compared to analyst estimates of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. As a group, analysts forecast that BioNTech SE will post -2 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.